Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation

Current Opinion in Oncology

Volumn 11, Issue 2, 1999, Pages 96-101

  Aguilar, Laura K ^a   Rooney, Cliona M ^a   Heslop, Helen E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN;

ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; BLOOD DONOR; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; T LYMPHOCYTE; VIRUS TRANSMISSION;

B-LYMPHOCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; RISK FACTORS; T-LYMPHOCYTES;

EID: 0032990280     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199903000-00004     Document Type: Review

References (57)

1. Rickinson AB, Moss DJ: Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997, 15:405-431. This is an excellent review of viral and host factors which affect the immune response to EBV in healthy individuals as well as in patients with EBV-associated tumors.
2. Lucas K, Small T, Heller G, Dupont B, O'Reilly RJ: The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996, 87:2594-2603.
3. Orazi A, Hromas RA, Neiman RS, Greiner TC, Lee CH, Rubin L, et al.: Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997, 107:419-429.
4. Deeg HJ, Socie G: Malignancies after hemopoietic stem cell transplantation: many questions, some answers. Blood 1998, 91:1833-1844. This is a comprehensive review of malignancies after stem cell transplantation which includes an excellent overview of EBV-LPD.
5. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995, 85:552-565.
6. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C: Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994, 83:2715-2722.
7. Riddler SA, Breinig MC, McKnight JLC: Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of post-transplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994, 84:972-984.
8. Fontan J, Bassignot A, Mougin C, Cahn JY, Lab M: Detection of Epstein-Barr virus DNA in serum of transplanted patients: a new diagnostic guide for lymphoproliferative diseases. Leukemia 1998, 12:772.
9. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE: Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol 1995, 89:98-103.
10. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, et al.: Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998, 91:3654-3661. These authors provide evidence that increased EBV load as measured by EBV polymerase chain reaction of blood leukocytes correlates with a high risk of impending LPD. They also review the Indiana University experience with different treatment approaches for LPD including donor leukocytes and advocate early intervention.
11. Liebowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Mad 1998, 338:1413-1421. This paper describes the molecular mechanism of the growth-promoting effect of EBV LMP1 in LPD and other EBV-associated tumors.
12. Kershaw GR, Berger C, McQuain C, Al-Homsi AS, Pihan G, Quesenberry PJ, et al.: Selective outgrowth of a posttransplant B-immunoblastic lymphoma expressing a latent membrane protein-1 deletion variant. Transplantation 1998, 64:1079-1081.
13. Tao Q, Ambinder RF, Swinnen LJ: Correspondence. Am J Pathol 1998, 152:1398-1399.
14. Scheinfield AG, Nador RG, Cesarman E, Chadburn A, Knowles DM: Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders. Am J Pathol 1997, 151:805-812. The authors provide evidence that a deletion-bearing variant of LMP1 is not clinically significant in solid organ transplant patients with LPD.
15. Beatty PR, Krams SM, Martinez OM: Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 1997, 158:4045-4051.
16. Nazaruk RA, Rochford R, Hobbs MV, Cannon MJ: Functional diversity of the CD8+ T-cell response to Epstein-Barr virus (EBV): Implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood 1998, 91:3875-3883. This study suggests that the CD8+ T-cell response to EBV includes cells secreting the type 2 cytokines IL-4 and IL-13 which may activate EBV-infected B cells.
17. Cannon MJ, Reed LD, Mawulawde K: Evidence for a type 2 bias in the CD8+ T-cell response to Epstein-Barr virus following heart transplantation. Transplant Proc 1998, 30:1136-1139.
18. Van der Pouw Kraan TCTM, Boeije LCM, Troon JTM, Rutschmann SK, Wijdenes J, Aarden LA: Human IL-13 production is negatively influenced by CD3 engagement. Enhancement of IL-13 production by cyclosporin A. J Immunol 1996, 156:1818-1823.
19. Mathur A, Kamat D, Filipovitch A, Steinbuch M, Shapiro R: Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders. Transplantation 1994, 57:1042-1045.
20. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L: Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997, 157:195-216. This review provides a comprehensive overview of the biology of EBV lymphoproliferative disease and updates the experience at Sloan Kettering Cancer Center with using donor T cells to treat this complication.
21. Heslop HE, Rooney CM: Adoptive immunotherapy of EBV lymphoproliferative diseases. Immunol Rev 1997, 157:217-222. This review outlines the rationale for the use of EBV-specific CTLs to treat EBV lymphoproliferative disease and discusses logistics, feasibility, and results of this approach.
22. Skinner JC, Gilbert EF, Hong R, Bozdech MJ, Flynn B, Borcherding W, et al.: B cell lymphoproliferative disorders following T cell depleted allogeneic bone marrow transplantation. Am J Pediatr Hematol Oncol 1988, 10:112-119.
23. Gerritsen EJ, Stam ED, Hermans J, Van den Berg H, Haraldsson A, Van Tol MJ, et al.: Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996, 18:377-382.
24. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, et al.: Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995, 85:2354-2363.
25. Hale G, Waldmann H: Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998, 91:3079-3083. This review of the experience using the Campath antibody for T cell depletion describes a low incidence of LPD indicating that removal of B cells as well as T cells may reduce the risk of LPD in hemopoietic stem cell transplantation recipients.
26. Gross TG, Hinrichs SH, Davis JR, Mitchell D, Bishop MR, Wagner JE: Depletion of EBV-infected cells in donor marrow by counterflow elutriation. Exp Hematol 1998, 26:395-399.
27. Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I: Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A 1988, 85:8693-8696.
28. Shepherd JD, Gascoyne RD, Barnett MJ, Coghlan JD, Phillips GL: Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995, 15:639-641.
29. Chao NJ, Berry GJ, Advani R, Horning SJ, Weiss LM, Blume KG: Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation 1993, 55:1425-1428.
30. Peniket AJ, Perry AR, Williams CD, MacMillan A, Watts MJ, Isaacson PG, et al.: A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor transplantation. Bone Marrow Transplant 1998, 22:307-309.
31. Briz M, Fores R, Regidor C, Busto M-J, Cajal SRY, Cabrera R, et al.: Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukemia. Br J Haematol 1997, 98:485-487.
32. Hauke RJ, Greiner TC, Smir BN, Vose JM, Tarantolo SR, Bashir RM, Bierman PJ: Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant 1998, 21:1271-1274.
33. Buckingham SC, Benaim E, Sandlund JT, Gan YJ, Freiden PJ, Behm FG, et al.: Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukemia: consecutive Epstein-Barr virus-related malignancies. Br J Haematol 1998, 101:345-348.
34. Starzl TE, Naleskin MA, Porter KA, Ho M, Iwataski S, Griffith BP, et al.: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1:583-587.
35. Swinnen U: Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am 1998, 11:963-973.
36. Heslop HE, Li C, Krance RA, Loftin SK, Rooney CM: Epstein-Barr infection after bone marrow transplantation. Blood 1994, 83:1706-1708.
37. Gross TG, Steinbuch M, Defor T, Shapiro RS, McGlave P, Ramsay NKC, et al.: B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999, in press. A review of the Minnesota experience regarding risk factors and treatment approaches for LPD in hemopoietic stem cell transplantation patients.
38. Papadopoulos EB, Ladanyi M, Emanuel D, MacKinnon S, Boulad F, Carabasi MH, et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
39. Rooney CM, Smith CA, Ng C, Loftin SK, Li C, Krance RA, et al.: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995, 345:9-13.
40. Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA, et al.: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
41. Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, et al.: Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1998, 63:1200-1205. These authors describe successful treatment of LPD in several solid organ transplantation patients with autologous lymphokine-activated killer cells.
42. Heslop HE, Brenner MK, Rooney CM: Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994, 331:679-680.
43. Sasahara Y, Kawai S, Itano M, Kumaki S, Fujie H, Minegishi M, et al.: Epstein-Barr virus-associated lymphoproliferative disorder after unrelated bone marrow transplantation in a young child with Wiskott-Aldrich syndrome. Pediatr Hematol Oncol 1998, 15:347-352.
44. Nagafuji K, Eto T, Hayashi S, Oshima K, Maeda Y, Gondo H, et al.: Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain. Bone Marrow Transplant 1998, 21:1155-1158.
45. Imashuku S, Goto T, Matsumura T, Naya M, Yamori M, Hojo M, et al.: Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant 1998, 20:337-340.
46. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al.: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science 1997, 276:1719-1724. This paper describes the effective use of donor leukocyte immunotherapy with a "suicide gene" strategy to reduce the risk of GVHD.
47. Rooney CM, Smith CA, Ng CYC, Loftin SK, Sixbey JW, Gan Y-J, et al.: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-1555. This article describes the safe and effective use of EBV-specific CTLs for prophylaxis of EBV-LPD in high risk recipients. The authors also outline the clinical course of a patient who responded to CTLs as therapy but experienced morbidity from tissue inflammation during therapeutic response.
48. Gottschalk S, Ng CYC, Perez M, Brenner MK, Heslop HE, Rooney CM: Mutation in EBV produces immunoblastic lymphoma unresponsive to CTL immunotherapy [abstract]. Blood 1998, 92:321a.
49. Smith CA, Ng CYC, Heslop HE, Holladay MS, Richardson S, Turner EV, et al.: Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995, 4:73-79.
50. Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE: Immunotherapy of EBV lymphoma. J Natl Cancer Inst Monogr 1998, 23:89-93.
51. Orentas RJ, Lemas MV, Mullin MJ, Colombani PM, Schwartz K, Ambinder R: Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors. J Hematother 1998, 7:257-261.
52. Emanuel DJ, Lucas KG, Mallory GB, Edwards-Brown MK, Pollok KE, Conrad PD, et al.: Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997, 63:1691-1694.
53. Fischer A, Blanche S, Lebidois J, Bordigoni P, Gamier JL, Neaudet P, et al.: Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991, 324:1451-1456.
54. Leblond V, Sutton L, Dorent R, Davi F, Bitker M-O, Gabarre J, et al.: Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1996, 13:961-968.
55. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
56. Chodosh J, Holder VP, Gan Y-J, Belgaumi A, Sample J, Sixbey JW: Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis 1998, 177:1194-1201.
57. Huang S, Stupack D, Mathias P, Wang Y, Nemerow GR: Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Proc Natl Acad Sci U S A 1997, 94:8156-8161.